- Lessons from moving regenerative practices beyond demonstration projects.
- Financing and policy levers that unlock widespread adoption.
- How to accelerate uptake without losing integrity
- How sanctions, trade restrictions, or export bans impact access to critical ingredients.
- Mapping vulnerabilities in agriculture, natural and synthetic ingredient supply chains
- Strategies for diversifying sourcing regions and suppliers.
Patrick Grady
CEO
TetraScience
Patrick serves as co-founder, chairman, and CEO of TetraScience. Prior to TetraScience, Patrick spent three decades building, backing, and scaling market-defining companies and technology stacks within the high-performance computing, SaaS, cloud, and AI markets.
Patrick was the founder, CEO, and CTO of the first intelligent agent company of the Internet era, built one of the world’s first three SaaS companies, the first enterprise SaaS business, one of the first ten global technology unicorns, and the first AI unicorn.
To deliver these AI agents to market, Patrick played a well-documented role in pioneering and/or commercializing several enabling technologies, including web services, SOA, and multi-tenancy, which now undergird the trillion-dollar cloud market.
Recognized as a leading innovator by numerous publications and peer groups over the years, Patrick was a recipient of the 2006 Fast Company award, given to the top 50 people in the world most likely to change the way we live and work for his seminal efforts in personal agent AI.
Lydia Gushgari, PhD
Chief of Staff
SPOC Biosciences
Jim Villa
Global Head, Research Strategy & Operations
Takeda
- Developing a mechanistic model of IVT to include nucleation and growth of magnesium pyrophosphate crystals and subsequent agglomeration of crystals and DNA.
Nathan Stover
Engineer
BioCurie
Zhaoqian Su
AI Scientist
Takeda
Melissa Landon
Head, Commercial & Business Development, AI & Automation
MilliporeSigma
Dr. Melissa (“Mel”) Landon leads Commercial and Business Development for AI and Automation at Millipore Sigma, the Life Science business of Merck KGaA. With 20 years of experience of building cutting edge platforms across pharma and tech, Mel’s current work focuses on scaling intelligent automation and AI solutions that bridge scientific innovation with commercial value. She brings to this role a cross-disciplinary background spanning life sciences, technology partnerships, and enterprise transformation. Prior to joining MilliporeSigma, Melissa served as Chief Strategy Officer at Cyclica, an AI-enabled tech bio company (acquired by Recursion in 2023). Melissa completed her PhD in Bioinformatics at Boston University and performed postdoctoral studies in biochemistry and X-ray crystallography at Brandeis University.
Sagar Jain
Director, Digital AI Strategy SSF
Roche
Steve Gately
Client Director, Healthcare ISV Platforms
NVIDIA
Steve leads NVIDIA’s engagement with strategic ISV platform partners in the healthcare sector, helping them accelerate their go-to-market initiatives. By integrating partners’ specialized tools and data with NVIDIA’s advanced training and inference technologies, Steve and his team develop cohesive strategies that drive success across key AI-powered healthcare use cases.